

AMENDMENTS TO THE CLAIMS

1. (Currently Amended) A method for improving the vision of a user having an eye disorder attributable to systemic inflammation which comprises;

administering on a daily basis for a period of at least 2 days, a composition consisting essentially of:

(a) from about 1 to about 20 milligrams of a leukotriene inhibitor,

(b) from about 50 to about 250 milligrams of an antihistamine, and

(c) from about 110mcg to about 220 mcg of a corticosteroid

wherein C- reactive protein levels in the body of the user are reduced to abate the inflammation to thereby improve the vision of the user, and further wherein the leukotriene inhibitor and the antihistamine are each orally ingested and the corticosteroid is administered as a nasal spray.

2. (Cancelled)

3. (Currently Amended) of claim 2 1 wherein the selected composition is used in an amount of:

(a) from about 5 to about 15 milligrams of the leukotriene inhibitor,

(b) from about 175 to about 200 milligrams of the antihistamine, and

(c) from about 110 µcg to about 220µcg of the corticosteroid.

4. (Currently Amended) The method of claim 2 1 wherein the leukotriene inhibitor is selected from the group consisting of:

zafirlukast, zileuton, and mixtures thereof.

5. (Currently Amended) The method of claim 2 1 wherein the antihistamine is selected from the group consisting of:

cetirizine, fexofenadine, loratadine, and azelastine.

6. (Currently Amended) The method of claim 2 1 wherein the steroid is selected from the group consisting of:

mometasone furoate monohydrate, triamcinolone, acetonide, and budesonide.

7. (Currently Amended) The method of claim 2 1 wherein:

(a) the leukotriene inhibitor is montelukast sodium,

(b) the antihistamine is selected from the group consisting of cetirizine, fexofenadine and loratadine, and

(c) the steroid is fluticasone propionate.

8. (Cancelled)

9. (Currently Amended) The method of claim 2 1 wherein:

the leukotriene and the antihistamine are administered orally and the steroid is nasally infused.

10-17. (Withdrawn)

18. (Currently Amended) A method for improving the vision of a user having an eye disorder attributable to systemic inflammation by lowering C-reactive protein levels in the body thereof which comprises:

administering on a daily basis for a period of at least 2 days, a composition consisting essentially of:

- (a) from about 1 to about 20 milligrams of a leukotriene inhibitor,
- (b) from about 50 to about 250 milligrams of an antihistamine, and
- (c) from about 110mcg to about 220 mcg of a corticosteroid

wherein C- reactive protein levels in the body of the user are reduced to abate the inflammation to thereby improve the vision of the user, and further wherein the leukotriene inhibitor and the antihistamine are each orally ingested and the corticosteroid is administered as a nasal spray.

19. (Cancelled)

20. (Previously Amended) The method of claim 18 wherein:

- (a) the leukotriene inhibitor is a montelukast sodium, the inhibitor being used in an amount ranging from about 5 to about 15 milligrams,
- (b) the antihistamine is selected from the group consisting of cetirizine, fexofenadine and loratadine, the antihistamine being used in an amount ranging from about 175 to about 200 milligrams, and

(c) the steroid is selected from the group consisting of:

mometasone furoate monohydrate, triamcinolone, acetonide, and budesonide, the steroid being used in an amount ranging from about 110 µcg to about 220 µcg.